NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Rating of “Moderate Buy” from Analysts

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has been assigned a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, ten have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $49.7273.

A number of research analysts recently issued reports on NAMS shares. Royal Bank Of Canada dropped their price objective on shares of NewAmsterdam Pharma from $51.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Friday, July 17th. BMO Capital Markets initiated coverage on shares of NewAmsterdam Pharma in a research report on Monday, July 20th. They issued an “outperform” rating and a $58.00 price target for the company. Jefferies Financial Group reaffirmed a “buy” rating and set a $45.00 price target on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. Finally, HC Wainwright reiterated a “buy” rating and set a $52.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday.

Insider Activity at NewAmsterdam Pharma

In related news, CAO Louise Kooij sold 105,000 shares of the company’s stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $30.34, for a total value of $3,185,700.00. Following the sale, the chief accounting officer directly owned 24,353 shares in the company, valued at $738,870.02. This represents a 81.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director John W. Smither sold 1,600 shares of the stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $25.32, for a total transaction of $40,512.00. Following the sale, the director directly owned 8,760 shares of the company’s stock, valued at $221,803.20. This represents a 15.44% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 271,600 shares of company stock worth $7,797,962 over the last three months. Company insiders own 12.74% of the company’s stock.

Institutional Investors Weigh In On NewAmsterdam Pharma

A number of institutional investors have recently modified their holdings of NAMS. Wells Fargo & Company MN increased its position in shares of NewAmsterdam Pharma by 50.0% during the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after buying an additional 300 shares during the period. Geode Capital Management LLC lifted its holdings in NewAmsterdam Pharma by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 102,395 shares of the company’s stock valued at $3,590,000 after buying an additional 437 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in NewAmsterdam Pharma by 5.3% in the second quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock valued at $197,000 after buying an additional 544 shares during the period. AlphaCentric Advisors LLC boosted its position in NewAmsterdam Pharma by 6.7% during the first quarter. AlphaCentric Advisors LLC now owns 14,656 shares of the company’s stock valued at $469,000 after acquiring an additional 925 shares during the last quarter. Finally, KBC Group NV bought a new stake in NewAmsterdam Pharma during the first quarter valued at $37,000. 89.89% of the stock is owned by institutional investors.

NewAmsterdam Pharma Trading Up 4.3%

NewAmsterdam Pharma stock opened at $22.80 on Friday. The company has a market capitalization of $2.73 billion, a PE ratio of -10.56 and a beta of 0.09. NewAmsterdam Pharma has a 12 month low of $21.23 and a 12 month high of $42.21. The stock has a 50-day moving average price of $28.60 and a two-hundred day moving average price of $31.22.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). The firm had revenue of $3.70 million for the quarter, compared to analyst estimates of $2.83 million. NewAmsterdam Pharma had a negative net margin of 3,644.21% and a negative return on equity of 34.81%. As a group, analysts predict that NewAmsterdam Pharma will post -1.82 earnings per share for the current fiscal year.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases, particularly conditions involving elevated cholesterol and residual cardiovascular risk. The company’s lead product candidate is obicetrapib, an oral, low-dose cholesteryl ester transfer protein (CETP) inhibitor designed to reduce low-density lipoprotein cholesterol and improve other lipid parameters.

Obicetrapib has been evaluated in several clinical studies, including the Phase 3 BROADWAY trial, for patients whose cholesterol levels remain inadequately controlled despite the use of existing lipid-lowering treatments.